日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Sphingosine-1-Phosphate Receptor 3 Confers Tumor Metastasis in Lung Cancer Resistant to Third-Generation EGFR Inhibitor

鞘氨醇-1-磷酸受体3赋予对第三代EGFR抑制剂耐药的肺癌肿瘤转移能力

Lai, Mengzhen; Chen, Jiaying; Qin, Ye; Zhang, Hui; Pan, Zilu; Zhang, Tao; Tong, Linjiang; Tang, Haotian; Bai, Gang; Liu, Qiupei; Li, Yan; Feng, Fang; Song, Peiran; Liu, Yingqiang; Chen, Yi; Fang, Yan; Tang, Bencan; Geng, Meiyu; Yu, Ker; Chen, Hao; Ding, Jian; Xie, Hua

Design, synthesis and pharmacological evaluation of 3H-spiro[benzofuran-2,4'-piperidine] IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma

3H-螺[苯并呋喃-2,4'-哌啶]IRAK4抑制剂的设计、合成及药理学评价及其在弥漫性大B细胞淋巴瘤治疗中的应用

Chen, Zhiwei; Zhang, Qi; Chen, Yun; Ning, Yi; Zhang, Q-I; Zhang, Mengxiao; Liu, Qiupei; Xue, Yi; Tong, Linjiang; Ding, Jian; Xie, Hua; Duan, Wenhu

Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma.

SYHA1813 双重靶向 VEGFR2 和 CSF1R 为治疗 BRAF 野生型和突变型黑色素瘤提供了一种新的策略

Shi Wenhao, Tang Haotian, Tong Linjiang, Song Peiran, Huang Yuqing, Wan Zhipeng, Huang Gege, Liu Qiupei, Zhan Zhengsheng, Zhou Yu, Li Yuantong, Wen Jiaxin, Tang Bencan, Duan Wenhu, Ding Jian, Li Xiaorui, Xie Hua

A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy

一种通过靶向肿瘤微环境并协同增强抗PD-1免疫疗法来治疗癌基因突变肿瘤的新策略

Liu, Yingqiang; Tong, Linjiang; Zhang, Mengge; Zhang, Qi; Liu, Qiupei; Feng, Fang; Li, Yan; Lai, Mengzhen; Tang, Haotian; Chen, Yi; Geng, Meiyu; Duan, Wenhu; Ding, Jian; Xie, Hua

Discovery of novel SOS1 inhibitors using machine learning

利用机器学习发现新型SOS1抑制剂

Duo, Lihui; Chen, Yi; Liu, Qiupei; Ma, Zhangyi; Farjudian, Amin; Ho, Wan Yong; Low, Sze Shin; Ren, Jianfeng; Hirst, Jonathan D; Xie, Hua; Tang, Bencan